Repligen Corporation (RGEN)

Currency in USD
163.81
-6.48(-3.81%)
Closed·
163.810.00(0.00%)
·
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
162.47169.61
52 wk Range
100.99198.87
Key Statistics
Prev. Close
170.29
Open
169.61
Day's Range
162.47-169.61
52 wk Range
100.99-198.87
Volume
697.7K
Average Vol. (3m)
1.17M
1-Year Change
0.8%
Book Value / Share
37.06
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
203.21
Upside
+24.05%
Members' Sentiments
Bearish
Bullish
ProTips
15 analysts have revised their earnings downwards for the upcoming period

Repligen Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

16 Buy
4 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 203.21
(+24.05% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy207.00+26.37%-MaintainNov 02, 2026
RBC Capital
Buy20.00-87.79%185.00MaintainOct 28, 2026
Canaccord
Hold180.00+9.88%-MaintainOct 28, 2026
Canaccord
Hold180.00+9.88%145.00MaintainOct 19, 2026
Barclays
Buy225.00+37.35%175.00MaintainOct 07, 2026

Repligen Corporation SWOT Analysis


Analyst Perspectives
Price targets range from $150 to $220, with an average of $172.50, reflecting varied views on Repligen's growth potential and market position
Market Expansion
Explore Repligen's growth from a $4B addressable market in 2020 to $12B in 2024, driven by new modalities and digitization initiatives
Financial Resilience
Q1 2025 revenue surpassed expectations at $169.2M, with revised full-year guidance of $695M-$720M, despite earnings per share missing forecasts
Bioprocessing Pionee
Repligen leads the bioprocessing industry with innovative products and strategic acquisitions, navigating market recovery and industry challenges
Read full SWOT analysis

Repligen Corporation Earnings Call Summary for Q3/2026

  • Repligen posted Q3 2026 revenue of $209M (up 11% YoY) and adjusted EPS of $0.53, beating estimates of $206.7M and $0.46 per share respectively.
  • Organic revenue growth hit record 12.5%; Chromatography rose 50%+, Proteins 40%+, Analytics 20%, while Filtration declined 11% amid customer headwinds.
  • Company raised FY2026 guidance to $844M-$852M revenue with 12-13% organic growth; expects to exceed $1B revenue in 2027 for the first time.
  • BioLife acquisition closed in October, expected to add $24M in 2026 revenue and be at least $0.05 accretive to 2027 earnings with integration underway.
  • Shares fell 2.25% to $176.12 despite earnings beat as investors weighed timing delays in equipment revenue and near-term filtration weakness against outlook.
Last Updated: 10/27/2026, 09:12 AM
Read Full Transcript
Repligen investor slides for Q3/2026
Repligen Q3 2026 slides
Last Update: Oct 27, 2026
See full investor slides

Earnings

Latest Release
Oct 27, 2026
EPS / Forecast
0.53 / 0.46
Revenue / Forecast
209M / 206.7M
EPS Revisions
Last 90 days

RGEN Income Statement

Compare RGEN to Peers and Sector

Metrics to compare
RGEN
Peers
Sector
Relationship
P/E Ratio
−887.1x−0.4x−0.2x
PEG Ratio
0.960.070.00
Price / Book
5.0x5.6x2.6x
Price / LTM Sales
13.0x3.4x2.6x
Upside (Analyst Target)
24.1%30.9%76.9%
Fair Value Upside
Unlock8.5%14.9%Unlock

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
39.05M61.09%6.40B
Other Institutional Investors
35.43M38.91%5.80B
Public Companies & Retail Investors
0.000.00%0.00
Total
74.48M100.00%12.2B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC11.50%7,348,8931,203,822
BlackRock, Inc.8.96%5,726,731938,096

People Also Watch

87.39
DINO
-2.60%
64.63
EXEL
-1.82%
460.54
LITE
-13.94%
69.72
APH
-7.79%
180.35
ALAB
-14.77%

FAQ

What Is the Repligen (RGEN) Stock Price Today?

The Repligen stock price today is 163.81 USD.

What Stock Exchange Does Repligen Trade On?

Repligen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Repligen?

The stock symbol for Repligen is "RGEN."

What Is the Repligen Market Cap?

As of today, Repligen market cap is 10.89B USD.

What Is Repligen's Earnings Per Share (TTM)?

The Repligen EPS (TTM) is -0.21.

When Is the Next Repligen Earnings Date?

Repligen will release its next earnings report on Feb 24, 2027.

From a Technical Analysis Perspective, Is RGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Repligen Stock Split?

Repligen has split 0 times.

How Many Employees Does Repligen Have?

Repligen has 2000 employees.

What is the current trading status of Repligen (RGEN)?

As of Nov 21, 2026, Repligen (RGEN) is trading at a price of 163.81 USD, with a previous close of 170.29 USD. The stock has fluctuated within a day range of 162.47 USD to 169.61 USD, while its 52-week range spans from 100.99 USD to 198.87 USD.

What Is Repligen (RGEN) Price Target According to Analysts?

The average 12-month price target for Repligen is 203.21 USD, with a high estimate of 235 USD and a low estimate of 175 USD. 16 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +24.05% Upside potential.

What Is the RGEN Premarket Price?

RGEN's last pre-market stock price is 170.59 USD. The pre-market share volume is 240.00, and the stock has decreased by 0.30, or 0.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.